Angiotensin receptor blocker protection against podocyte-induced sclerosis is podocyte angiotensin II type 1 receptor-independent

Hypertension

Volumn 55, Issue 4, 2010, Pages 967-973

  Matsusaka, Taiji ^a,e   Asano, Takako ^g   Niimura, Fumio ^e   Kinomura, Masaru ^e   Shimizu, Akihiro ^d   Shintani, Ayumi ^h   Pastan, Ira ^f   Fogo, Agnes B ^a,b,c   Ichikawa, Iekuni ^a,c,e  

^a Departments of Medicine and Pediatrics   (United States)

^b Departments of Pathology   (United States)

^c VANDERBILT UNIVERSITY   (United States)

^d VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^e TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f NATIONAL CANCER INSTITUTE   (United States)

^g NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

AT1 antagonist; Chronic renal failure; Glomerulosclerosis; Knockout mice; Podocyte; Proteinuria

Indexed keywords

AGTR1A PROTEIN; AGTR1B PROTEIN; ALBUMIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN RECEPTOR; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDRALAZINE; IMMUNOTOXIN; LOSARTAN; UNCLASSIFIED DRUG; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FEMALE; GENE ACTIVATION; GENE DELETION; GENE DISRUPTION; GENE INACTIVATION; GLOMERULOSCLEROSIS; HORMONE INHIBITION; KNOCKOUT MOUSE; MALE; MICROALBUMINURIA; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PODOCYTE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEINURIA; RENAL PROTECTION; ANIMAL; BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; GLOMERULONEPHRITIS; KIDNEY; METABOLISM; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; SCLEROSIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; FEMALE; GLOMERULONEPHRITIS; KIDNEY; KIDNEY FAILURE, CHRONIC; MALE; MICE; MICE, KNOCKOUT; PODOCYTES; PROTEINURIA; RECEPTOR, ANGIOTENSIN, TYPE 1; SCLEROSIS;

EID: 77950498008     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.109.141994     Document Type: Article

References (36)

1. Anderson S, Diamond JR, Karnovsky MJ, Brenner BM. Mechanisms underlying transition from acute glomerular injury to late glomerular sclerosis in a rat model of nephrotic syndrome. J Clin Invest. 1988;82: 1757-1768.
2. Fogo A, Yoshida Y, Glick AD, Homma T, Ichikawa I. Serial micropuncture analysis of glomerular function in two rat models of glomerular sclerosis. J Clin Invest. 1988;82:322-330.
3. Benigni A, Tomasoni S, Gagliardini E, Zoja C, Grunkemeyer JA, Kalluri R, Remuzzi G. Blocking angiotensin II synthesis/activity preserves glo-merular nephrin in rats with severe nephrosis. J Am Soc Nephrol. 2001; 12:941-948.
4. Remuzzi A, Gagliardini E, Sangalli F, Bonomelli M, Piccinelli M, Benigni A, Remuzzi G. ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney Int. 2006;69:1124-1130.
5. Hiramatsu N, Hiromura K, Shigehara T, Kuroiwa T, Ideura H, Sakurai N, Takeuchi S, Tomioka M, Ikeuchi H, Kaneko Y, Ueki K, Kopp JB, Nojima Y. Angiotensin II type 1 receptor blockade inhibits the development and progression of HIV-associated nephropathy in a mouse model. J Am Soc Nephrol. 2007;18:515-527.
6. Suzuki K, Han GD, Miyauchi N, Hashimoto T, Nakatsue T, Fujioka Y, Koike H, Shimizu F, Kawachi H. Angiotensin II type 1 and type 2 receptors play opposite roles in regulating the barrier function of kidney glomerular capillary wall. Am J Pathol. 2007;170:1841-1853.
7. Smeets B, Steenbergen ML, Dijkman HB, Verrijp KN, te Loeke NA, Aten J, Steenbergen EJ, Wetzels JF. Angiotensin converting enzyme inhibition prevents development of collapsing focal segmental glomerulosclerosis in Thy-1.1 transgenic mice. Nephrol Dial Transplant. 2006;21:3087-3097.
8. Ma LJ, Nakamura S, Aldigier JC, Rossini M, Yang H, Liang X, Nakamura I, Marcantoni C, Fogo AB. Regression of glomerulosclerosis with high-dose angiotensin inhibition is linked to decreased plasminogen activator inhibitor-1. J Am Soc Nephrol. 2005;16:966-976.
9. Gross ML, Ritz E, Schoof A, Helmke B, Parkman A, Tulp O, Munter K, Amann K. Renal damage in the SHR/N-cp type 2 diabetes model: comparison of an angiotensin-converting enzyme inhibitor and endothelin receptor blocker. Lab Invest. 2003;83:1267-1277.
10. Koga K, Yamagishi S, Takeuchi M, Inagaki Y, Amano S, Okamoto T, Saga T, Makita Z, Yoshizuka M. CS-886, a new angiotensin II type 1 receptor antagonist, ameliorates glomerular anionic site loss and prevents progression of diabetic nephropathy in Otsuka Long-Evans Tokushima fatty rats. Mol Med. 2002;8:591-599.
11. Lombardi DM, Viswanathan M, Vio CP, Saavedra JM, Schwartz SM, Johnson RJ. Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent. Nephron. 2001;87:66-74.
12. Wang L, Flannery PJ, Spurney RF. Characterization of angiotensin II-receptor subtypes in podocytes. J Lab Clin Med. 2003;142:313-321.
13. Gloy J, Henger A, Fischer KG, Nitschke R, Mundel P, Bleich M, Schollmeyer P, Greger R, Pavenstadt H. Angiotensin II depolarizes podocytes in the intact glomerulus of the Rat. J Clin Invest. 1997;99: 2772-2781. (Pubitemid 27259825)
14. Nitschke R, Henger A, Ricken S, Gloy J, Muller V, Greger R, Pavenstadt H. Angiotensin II increases the intracellular calcium activity in podocytes of the intact glomerulus. Kidney Int. 2000;57:41-49.
15. Chen S, Lee JS, Iglesias-de la Cruz MC, Wang A, Izquierdo-Lahuerta A, Gandhi NK, Danesh FR, Wolf G, Ziyadeh FN. Angiotensin II stimulates alpha3(IV) collagen production in mouse podocytes via TGF-beta and VEGF signalling: implications for diabetic glomerulopathy. Nephrol Dial Transplant. 2005;20:1320-1328.
16. Kang YS, Park YG, Kim BK, Han SY, Jee YH, Han KH, Lee MH, Song HK, Cha DR, Kang SW, Han DS. Angiotensin II stimulates the synthesis of vascular endothelial growth factor through the p38 mitogen activated protein kinase pathway in cultured mouse podocytes. J Mol Endocrinol. 2006;36:377-388.
17. Doublier S, Salvidio G, Lupia E, Ruotsalainen V, Verzola D, Deferrari G, Camussi G. Nephrin expression is reduced in human diabetic nephropa-thy: evidence for a distinct role for glycated albumin and angiotensin II. Diabetes. 2003;52:1023-1030.
18. Brinkkoetter PT, Holtgrefe S, van der Woude FJ, Yard BA. Angiotensin II type 1-receptor mediated changes in heparan sulfate proteoglycans in human SV40 transformed podocytes. J Am Soc Nephrol. 2004;15:33-40.
19. Macconi D, Abbate M, Morigi M, Angioletti S, Mister M, Buelli S, Bonomelli M, Mundel P, Endlich K, Remuzzi A, Remuzzi G. Perms-elective dysfunction of podocyte-podocyte contact upon angiotensin II unravels the molecular target for renoprotective intervention. Am J Pathol. 2006;168:1073-1085.
20. Hsu HH, Hoffmann S, Endlich N, Velic A, Schwab A, Weide T, Schlatter E, Pavenstadt H. Mechanisms of angiotensin II signaling on cytoskeleton of podocytes. J Mol Med. 2008;86:1379-1394.
21. Hoffmann S, Podlich D, Hahnel B, Kriz W, Gretz N. Angiotensin II type 1 receptor overexpression in podocytes induces glomerulosclerosis in transgenic rats. J Am Soc Nephrol. 2004;15:1475-1487.
22. Kreitman RJ, Pastan I. Accumulation of a recombinant immunotoxin in a tumor in vivo: fewer than 1000 molecules per cell are sufficient for complete responses. Cancer Res. 1998;58:968-975.
23. Matsusaka T, Xin J, Niwa S, Kobayashi K, Akatsuka A, Hashizume H, Wang QC, Pastan I, Fogo AB, Ichikawa I. Genetic engineering of glo-merular sclerosis in the mouse via control of onset and severity of podocyte-specific injury. J Am Soc Nephrol. 2005;16:1013-1023.
24. Nishimura H, Matsusaka T, Fogo A, Kon V, Ichikawa I. A novel in vivo mechanism for angiotensin type 1 receptor regulation. Kidney Int. 1997; 52:345-355.
25. Asano T, Niimura F, Pastan I, Fogo AB, Ichikawa I, Matsusaka T. Permanent genetic tagging of podocytes: fate of injured podocytes in a mouse model of glomerular sclerosis. J Am Soc Nephrol. 2005;16: 2257-2262.
26. Takemoto M, Asker N, Gerhardt H, Lundkvist A, Johansson BR, Saito Y, Betsholtz C. A new method for large scale isolation of kidney glomeruli from mice. Am J Pathol. 2002;161:799-805.
27. Liang XB, Ma LJ, Naito T, Wang Y, Madaio M, Zent R, Pozzi A, Fogo AB. Angiotensin type 1 receptor blocker restores podocyte potential to promote glomerular endothelial cell growth. J Am Soc Nephrol. 2006;17: 1886-1895.
28. Kobori H, Nangaku M, Navar LG, Nishiyama A. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev. 2007;59:251-287.
29. Park S, Bivona BJ, Harrison-Bernard LM. Compromised renal micro-vascular reactivity of angiotensin type 1 double null mice. Am J Physiol Renal Physiol. 2007;293:F60-F67.
30. Yoshioka T, Rennke HG, Salant DJ, Deen WM, Ichikawa I. Role of abnormally high transmural pressure in the permselectivity defect of glomerular capillary wall: a study in early passive Heymann nephritis. Circ Res. 1987;61:531-538.
31. Burson JM, Aguilera G, Gross KW, Sigmund CD. Differential expression of angiotensin receptor 1A and 1B in mouse. Am J Physiol. 1994;267: E260-E267.
32. Crowley SD, Vasievich MP, Ruiz P, Gould SK, Parsons KK, Pazmino AK, Facemire C, Chen BJ, Kim HS, Tran TT, Pisetsky DS, Barisoni L, Prieto-Carrasquero MC, Jeansson M, Foster MH, Coffman TM. Glomer-ular type 1 angiotensin receptors augment kidney injury and inflammation in murine autoimmune nephritis. J Clin Invest. 2009;119:943-953.
33. Miyazaki Y, Tsuchida S, Nishimura H, Pope JCt, Harris RC, McKanna JM, Inagami T, Hogan BL, Fogo A, Ichikawa I. Angiotensin induces the urinary peristaltic machinery during the perinatal period. J Clin Invest. 1998;102:1489-1497.
34. Chen S, Ge Y, Si J, Rifai A, Dworkin LD, Gong R. Candesartan suppresses chronic renal inflammation by a novel antioxidant action independent of AT1R blockade. Kidney Int. 2008;74:1128-1138.
35. Izuhara Y, Nangaku M, Inagi R, Tominaga N, Aizawa T, Kurokawa K, van Ypersele de Strihou C, Miyata T. Renoprotective properties of an-giotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol. 2005;16:3631-3641.
36. Kawada N, Imai E, Karber A, Welch WJ, Wilcox CS. A mouse model of angiotensin II slow pressor response: role of oxidative stress. J Am Soc Nephrol. 2002;13:2860-2868.